Literature DB >> 12575851

IgA pemphigus: the first two Scandinavian cases.

Robert Gniadecki1, Anette Bygum, Ole Clemmensen, Else Svejgaard, Susanne Ullman.   

Abstract

IgA pemphigus is a rare neutrophilic acantholytic skin disorder with only approximately 70 cases reported in the indexed literature to date. Here we describe two patients with IgA pemphigus (subcorneal pustular dermatosis type and intraepithelial neutrophilic type) that to our knowledge are the first Scandinavian patients with this disease. Initially, both patients were misdiagnosed as subcorneal pustular dermatosis of Sneddon and Wilkinson and only subsequent careful immunofluorescence studies (in one case with confocal laser scanning microscopy) led to the correct diagnosis. Apart from the expected IgA depositions on epidermal cell surfaces, both patients demonstrated some degree of intercellular IgG-specific immunofluorescence. No circulating IgA autoantibodies were detected. One patient was treated with the standard regime comprising dapsone and prednisolone, whereas in the other case a novel methotrexate and prednisolone combination treatment showed marked clinical efficacy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12575851     DOI: 10.1080/000155502762064584

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  3 in total

1.  [IgA pemphigus. Successful treatment with mycophenolate mofetil].

Authors:  T Burchardt; A Büchau; T Ruzicka; M Megahed
Journal:  Hautarzt       Date:  2004-04       Impact factor: 0.751

2.  [Successful treatment of subcorneal pustular type of IgA pemphigus].

Authors:  U Raap; B Völker; H Petering; T Hashimoto; D Zillikens; A Kapp; T Werfel
Journal:  Hautarzt       Date:  2005-01       Impact factor: 0.751

3.  [IgA pemphigus of the subcorneal pustular dermatosis type. Successful therapy with a combination of dapsone and acitretin].

Authors:  B Monshi; L Richter; T Hashimoto; E Groiß; N Haensch; K Rappersberger
Journal:  Hautarzt       Date:  2012-06       Impact factor: 0.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.